Personalised therapy for cancer patients
Researchers from A*STAR Institute of Microelectronics (IME) Bioelectronics programme are developing a cost-effective and a more rapid way to help physicians assess the effectiveness of treatments to cancer patients. IME’s research will allow more frequent tracking of a patient’s response to the prescribed treatment, enabling the physician to better tailor dosages for radiation and/or chemotherapy - treatments that can be plagued with discomfort and serious side effects. The new device measures the level of circulating tumour cells (CTCs) in whole blood and it is expected to speed up the sample-to-answer process by more than 50%.
“There is currently only one clinically approved method for CTC analysis worldwide, and it takes 3 – 7 days to process,” said Associate Professor Richie Soong, Senior Principal Investigator, Cancer Science Institute of Singapore at the National University of Singapore, who provided consultation to the IME team on test design requirements.
Circulating tumour cells (CTCs) are cells that have detached from a primary tumour and their circulation levels in the blood stream track the progression of cancer. The detection of CTCs is usually based on the presence of specific biomarker on their surfaces. To detect CTCs among a sea of red and white blood cells is like looking for a needle in a haystack. The current practice of measuring CTC uses a combination of complex magnetic forces and specific antibody-antigen interactions to isolate the CTCs. This is followed by laborious fluorescent tagging of the CTC before they can be detected and measured. All these labour-intensive steps add up to a substantial total analysis cost, on top of other medical expenses and long waiting time that the patient has to bear.
Imaging techniques and biopsies are other methods of cancer diagnosis. However, these methods require the tumour to reach a considerable size before the tumour can be detected, making these methods not favourable for early diagnosis. Using CTCs to flag the presence of a tumour earlier will also be less invasive than surgical biopsy methods.
Soong envisions IME’s research endeavour will lower costs and speed up turnaround times for CTC analysis, allowing physicians to order the CTC test more frequently. This would facilitate a more informed and a faster decision making process, which promises better management and potentially improved outcomes for patients.
The IME approach uses antigen-coated magnetic beads to capture the CTCs. The captured CTCs on the magnetic beads are then isolated before the CTCs are directly detected on the specially-treated microelectrode array (MEA). This way, the level of CTC is inferred from the impedance reading obtained.
Dr Abdur Rub Abdur Rahman, Senior Research Engineer from IME’s Bioelectronics Programme, said, “Our preliminary results showed that our device can detect 1 CTC directly from a pure cell standard – showing great promise as a sensitive test for cancer diagnosis. For breast cancer, the detection of 5 CTCs in 7.5 ml of whole blood was reported as a minimal disease state. Future work will entail full integration of the different modules, improving the total analysis time and boosting the sensitivity – vital steps to getting the system ready for clinical testing. Our aim is to go from sample to answer in less than a day and to cap the cost at $100 per test. Comparatively, the clinically approved CTC method is priced at about USD $650 (approximately SGD $910). IME’s CTC test can be further developed to provide genetic information of the detected cancer cells that will be an important starting point for drug discovery leading to personalised medicine.”
Cancer is rated the number 2 killer in Singapore. From 2002 - 2006, there were 42,424 incidents of cancer diagnosed among the residents of Singapore.
Source: A*Star /...
Previous Story: New project aims to develop large-area smart textiles
Next Story: Strategies for more efficient thin-film solar cells
The Institute of Nanotechnology puts significant effort into ensuring that the information provided on its news pages is accurate and up-to-date. However, we cannot guarantee absolute accuracy. Consequently, the Institute of Nanotechnology disclaims any and all responsibility for inaccuracy, omission or any kind of deficiency in relation to the news items and articles hosted herein.
- 29 July 2014Nanotechnology and tyres: Greening industry and transport
- 22 July 2014Supporting Recommendations for Future Topics in Horizon 2020
- 17 June 20142014 edition of European NanoSafety Cluster Compendium now online
- 14 May 2014Gold nanoparticles for cancer treatment
- 22 April 2014Irish Materials Research Centre (AMBER) in World First Graphene Innovation
- View All